Begin main content


Last Updated: June 25, 2019
Result type: Reports
Project Number: SR0626-000
Product Line: Common Drug Review

Generic Name: glucagon

Brand Name: TBC

Manufacturer: Eli Lilly Canada Inc.

Indications: Severe hypoglycemic reactions

Manufacturer Requested Reimbursement Criteria1:

For the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated adult and pediatric patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates.

Submission Type: New

Project Status: Pending

Call For Patient Input: June 25, 2019

Patient Input Closed: August 15, 2019

Anticipated Date: July 24, 2019

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback